Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5583889 | Seminars in Arthritis and Rheumatism | 2017 | 36 Pages |
Abstract
Evidence from randomised trials suggests that most biological agents are effective as monotherapy. Although our confidence in the estimates is limited, etanercept or tocilizumab may be the optimal choice for most patients who need treatment with biological monotherapy. However, given our limited confidence in the estimates including possibility of bias, it is appropriate to strongly weight patients׳ preferences and values in the final treatment choice.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Simon MSc, PhD, Daniel E. MD, Anna MD, Mikkel MD, PhD, DMSc, Tove MD, Michael S. MD, PhD, Jasvinder A. MD, MPH, Ernest H. MD, FRCP, Maarten MSc, MD, PhD, Maria E. MD, PhD, Lars E. MD, PhD, Henning MD, DMSc, Robin BSc, MSc, PhD,